Exclusive Summary

• Distinct Dosage Form Advantage: Dispersible tablets provide exceptional compliance for pediatric and dysphagic patients, serving as a superior and highly portable alternative to traditional dry antibiotic suspensions.
• Highly Flexible Packaging Configurations: Offered in versatile pack sizes (4, 6, 10, 12 tablets) across 0.25 g and 0.5 g strengths, precisely accommodating country-specific short-course antibiotic protocols (e.g., 3/5/7-day regimens) to minimize medication waste.
• Robust and Rigid Market Demand: As a widely prescribed 2nd-generation cephalosporin, it targets hundreds of millions of RTIs and AOM cases globally every year, acting as a preferred 1st or 2nd-line therapy for penicillin-resistant or allergic patients.
• Fast Commercialization with High Margins: With originator patents long expired and backed by China's dominant cost-efficient cephalosporin supply chain, the distribution partnership model enables overseas agents to achieve rapid market authorization with substantial profit margins.